English
简体中文
Total: £ 56.28
Published Date: 2026-04-17 | Pages: 118 | Tables: 111 | Medical Care
The global Leukemia Molecular Diagnostics market was valued at US$ 2312 million in 2025 and is anticipated to reach US$ 4564 million by 2032, at a CAGR of 10.4% from 2026 to 2032.
Molecular diagnosis of leukemia is a method of diagnosing and classifying leukemia by detecting specific gene mutations, chromosomal abnormalities or other molecular markers in leukemia patients. This diagnostic technology uses advanced molecular biology tools such as PCR (polymerase chain reaction), gene sequencing and fluorescence in situ hybridization (FISH) to identify molecular features in leukemia cells. Molecular diagnosis of leukemia not only helps to diagnose the disease, but also can accurately classify leukemia subtypes, providing an important basis for the formulation of individualized treatment plans. This precise diagnostic method helps to assess the patient's prognosis, monitor the effectiveness of treatment, and detect the risk of recurrence at an early stage. It is an indispensable tool in modern leukemia management.
The increasing adoption of personalized medicine is a key driver for the leukemia molecular diagnostics market. Advances in molecular diagnostic technologies, such as next-generation sequencing (NGS) and polymerase chain reaction (PCR), enable precise genetic profiling of leukemia, leading to more targeted and effective treatment plans. This personalized approach not only improves patient outcomes but also boosts demand for molecular diagnostics in leukemia management.
One of the main challenges in the leukemia molecular diagnostics market is the high cost associated with advanced diagnostic tools and testing procedures. These technologies often require significant investment in equipment, skilled personnel, and infrastructure, which can limit accessibility in low-resource settings, reducing the potential reach of molecular diagnostics in leukemia care.
This report delivers a comprehensive overview of the global Leukemia Molecular Diagnostics market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Leukemia Molecular Diagnostics. The Leukemia Molecular Diagnostics market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Leukemia Molecular Diagnostics market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Leukemia Molecular Diagnostics manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Ruiang Gene
Zhishan Bio
Zhijiang Bio
Jinpujia Medical
Merle Bio
Herui Gene
Aicon Bio
Annuouda
Beijing Wantai
Haixi Bio
Qiagen
Abbott
Kanglu Biotechnology
Guangzhou Anbiping
Segment by Type
PCR
FISH
DNA Sequencing
Gene Chip
Segment by Application
Clinical Diagnosis
Drug Screening
Research
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Rest of Asia
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Rest of MEA
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Leukemia Molecular Diagnostics companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Leukemia Molecular Diagnostics Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 PCR
1.2.3 FISH
1.2.4 DNA Sequencing
1.2.5 Gene Chip
1.3 Market by Application
1.3.1 Global Leukemia Molecular Diagnostics Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Clinical Diagnosis
1.3.3 Drug Screening
1.3.4 Research
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Leukemia Molecular Diagnostics Market Perspective (2021–2032)
2.2 Global Leukemia Molecular Diagnostics Growth Trends by Region
2.2.1 Global Leukemia Molecular Diagnostics Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Leukemia Molecular Diagnostics Historic Market Size by Region (2021–2026)
2.2.3 Leukemia Molecular Diagnostics Forecasted Market Size by Region (2027–2032)
2.3 Leukemia Molecular Diagnostics Market Dynamics
2.3.1 Leukemia Molecular Diagnostics Industry Trends
2.3.2 Leukemia Molecular Diagnostics Market Drivers
2.3.3 Leukemia Molecular Diagnostics Market Challenges
2.3.4 Leukemia Molecular Diagnostics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Leukemia Molecular Diagnostics Players by Revenue
3.1.1 Global Top Leukemia Molecular Diagnostics Players by Revenue (2021–2026)
3.1.2 Global Leukemia Molecular Diagnostics Revenue Market Share by Players (2021–2026)
3.2 Global Top Leukemia Molecular Diagnostics Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Leukemia Molecular Diagnostics Revenue
3.4 Global Leukemia Molecular Diagnostics Market Concentration Ratio
3.4.1 Global Leukemia Molecular Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Leukemia Molecular Diagnostics Revenue in 2025
3.5 Global Key Players of Leukemia Molecular Diagnostics Head Offices and Areas Served
3.6 Global Key Players of Leukemia Molecular Diagnostics, Products and Applications
3.7 Global Key Players of Leukemia Molecular Diagnostics, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Leukemia Molecular Diagnostics Breakdown Data by Type
4.1 Global Leukemia Molecular Diagnostics Historic Market Size by Type (2021–2026)
4.2 Global Leukemia Molecular Diagnostics Forecasted Market Size by Type (2027–2032)
5 Leukemia Molecular Diagnostics Breakdown Data by Application
5.1 Global Leukemia Molecular Diagnostics Historic Market Size by Application (2021–2026)
5.2 Global Leukemia Molecular Diagnostics Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Leukemia Molecular Diagnostics Market Size (2021–2032)
6.2 North America Leukemia Molecular Diagnostics Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Leukemia Molecular Diagnostics Market Size by Country (2021–2026)
6.4 North America Leukemia Molecular Diagnostics Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Leukemia Molecular Diagnostics Market Size (2021–2032)
7.2 Europe Leukemia Molecular Diagnostics Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Leukemia Molecular Diagnostics Market Size by Country (2021–2026)
7.4 Europe Leukemia Molecular Diagnostics Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Leukemia Molecular Diagnostics Market Size (2021–2032)
8.2 Asia-Pacific Leukemia Molecular Diagnostics Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Leukemia Molecular Diagnostics Market Size by Region (2021–2026)
8.4 Asia-Pacific Leukemia Molecular Diagnostics Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Leukemia Molecular Diagnostics Market Size (2021–2032)
9.2 Latin America Leukemia Molecular Diagnostics Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Leukemia Molecular Diagnostics Market Size by Country (2021–2026)
9.4 Latin America Leukemia Molecular Diagnostics Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Leukemia Molecular Diagnostics Market Size (2021–2032)
10.2 Middle East & Africa Leukemia Molecular Diagnostics Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Leukemia Molecular Diagnostics Market Size by Country (2021–2026)
10.4 Middle East & Africa Leukemia Molecular Diagnostics Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Ruiang Gene
11.1.1 Ruiang Gene Company Details
11.1.2 Ruiang Gene Business Overview
11.1.3 Ruiang Gene Leukemia Molecular Diagnostics Introduction
11.1.4 Ruiang Gene Revenue in Leukemia Molecular Diagnostics Business (2021–2026)
11.1.5 Ruiang Gene Recent Development
11.2 Zhishan Bio
11.2.1 Zhishan Bio Company Details
11.2.2 Zhishan Bio Business Overview
11.2.3 Zhishan Bio Leukemia Molecular Diagnostics Introduction
11.2.4 Zhishan Bio Revenue in Leukemia Molecular Diagnostics Business (2021–2026)
11.2.5 Zhishan Bio Recent Development
11.3 Zhijiang Bio
11.3.1 Zhijiang Bio Company Details
11.3.2 Zhijiang Bio Business Overview
11.3.3 Zhijiang Bio Leukemia Molecular Diagnostics Introduction
11.3.4 Zhijiang Bio Revenue in Leukemia Molecular Diagnostics Business (2021–2026)
11.3.5 Zhijiang Bio Recent Development
11.4 Jinpujia Medical
11.4.1 Jinpujia Medical Company Details
11.4.2 Jinpujia Medical Business Overview
11.4.3 Jinpujia Medical Leukemia Molecular Diagnostics Introduction
11.4.4 Jinpujia Medical Revenue in Leukemia Molecular Diagnostics Business (2021–2026)
11.4.5 Jinpujia Medical Recent Development
11.5 Merle Bio
11.5.1 Merle Bio Company Details
11.5.2 Merle Bio Business Overview
11.5.3 Merle Bio Leukemia Molecular Diagnostics Introduction
11.5.4 Merle Bio Revenue in Leukemia Molecular Diagnostics Business (2021–2026)
11.5.5 Merle Bio Recent Development
11.6 Herui Gene
11.6.1 Herui Gene Company Details
11.6.2 Herui Gene Business Overview
11.6.3 Herui Gene Leukemia Molecular Diagnostics Introduction
11.6.4 Herui Gene Revenue in Leukemia Molecular Diagnostics Business (2021–2026)
11.6.5 Herui Gene Recent Development
11.7 Aicon Bio
11.7.1 Aicon Bio Company Details
11.7.2 Aicon Bio Business Overview
11.7.3 Aicon Bio Leukemia Molecular Diagnostics Introduction
11.7.4 Aicon Bio Revenue in Leukemia Molecular Diagnostics Business (2021–2026)
11.7.5 Aicon Bio Recent Development
11.8 Annuouda
11.8.1 Annuouda Company Details
11.8.2 Annuouda Business Overview
11.8.3 Annuouda Leukemia Molecular Diagnostics Introduction
11.8.4 Annuouda Revenue in Leukemia Molecular Diagnostics Business (2021–2026)
11.8.5 Annuouda Recent Development
11.9 Beijing Wantai
11.9.1 Beijing Wantai Company Details
11.9.2 Beijing Wantai Business Overview
11.9.3 Beijing Wantai Leukemia Molecular Diagnostics Introduction
11.9.4 Beijing Wantai Revenue in Leukemia Molecular Diagnostics Business (2021–2026)
11.9.5 Beijing Wantai Recent Development
11.10 Haixi Bio
11.10.1 Haixi Bio Company Details
11.10.2 Haixi Bio Business Overview
11.10.3 Haixi Bio Leukemia Molecular Diagnostics Introduction
11.10.4 Haixi Bio Revenue in Leukemia Molecular Diagnostics Business (2021–2026)
11.10.5 Haixi Bio Recent Development
11.11 Qiagen
11.11.1 Qiagen Company Details
11.11.2 Qiagen Business Overview
11.11.3 Qiagen Leukemia Molecular Diagnostics Introduction
11.11.4 Qiagen Revenue in Leukemia Molecular Diagnostics Business (2021–2026)
11.11.5 Qiagen Recent Development
11.12 Abbott
11.12.1 Abbott Company Details
11.12.2 Abbott Business Overview
11.12.3 Abbott Leukemia Molecular Diagnostics Introduction
11.12.4 Abbott Revenue in Leukemia Molecular Diagnostics Business (2021–2026)
11.12.5 Abbott Recent Development
11.13 Kanglu Biotechnology
11.13.1 Kanglu Biotechnology Company Details
11.13.2 Kanglu Biotechnology Business Overview
11.13.3 Kanglu Biotechnology Leukemia Molecular Diagnostics Introduction
11.13.4 Kanglu Biotechnology Revenue in Leukemia Molecular Diagnostics Business (2021–2026)
11.13.5 Kanglu Biotechnology Recent Development
11.14 Guangzhou Anbiping
11.14.1 Guangzhou Anbiping Company Details
11.14.2 Guangzhou Anbiping Business Overview
11.14.3 Guangzhou Anbiping Leukemia Molecular Diagnostics Introduction
11.14.4 Guangzhou Anbiping Revenue in Leukemia Molecular Diagnostics Business (2021–2026)
11.14.5 Guangzhou Anbiping Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Leukemia Molecular Diagnostics Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of PCR
Table 3. Key Players of FISH
Table 4. Key Players of DNA Sequencing
Table 5. Key Players of Gene Chip
Table 6. Global Leukemia Molecular Diagnostics Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 7. Global Leukemia Molecular Diagnostics Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 8. Global Leukemia Molecular Diagnostics Market Size by Region (US$ Million), 2021–2026
Table 9. Global Leukemia Molecular Diagnostics Market Share by Region (2021–2026)
Table 10. Global Leukemia Molecular Diagnostics Forecasted Market Size by Region (US$ Million), 2027–2032
Table 11. Global Leukemia Molecular Diagnostics Market Share by Region (2027–2032)
Table 12. Leukemia Molecular Diagnostics Market Trends
Table 13. Leukemia Molecular Diagnostics Market Drivers
Table 14. Leukemia Molecular Diagnostics Market Challenges
Table 15. Leukemia Molecular Diagnostics Market Restraints
Table 16. Global Leukemia Molecular Diagnostics Revenue by Players (US$ Million), 2021–2026
Table 17. Global Leukemia Molecular Diagnostics Market Share by Players (2021–2026)
Table 18. Global Top Leukemia Molecular Diagnostics Players by Tier (Tier 1, Tier 2, and Tier 3), based on Leukemia Molecular Diagnostics Revenue, 2025
Table 19. Ranking of Global Top Leukemia Molecular Diagnostics Companies by Revenue (US$ Million) in 2025
Table 20. Global 5 Largest Players Market Share by Leukemia Molecular Diagnostics Revenue (CR5 and HHI), 2021–2026
Table 21. Global Key Players of Leukemia Molecular Diagnostics, Headquarters and Area Served
Table 22. Global Key Players of Leukemia Molecular Diagnostics, Products and Applications
Table 23. Global Key Players of Leukemia Molecular Diagnostics, Date of General Availability (GA)
Table 24. Mergers and Acquisitions, Expansion Plans
Table 25. Global Leukemia Molecular Diagnostics Market Size by Type (US$ Million), 2021–2026
Table 26. Global Leukemia Molecular Diagnostics Revenue Market Share by Type (2021–2026)
Table 27. Global Leukemia Molecular Diagnostics Forecasted Market Size by Type (US$ Million), 2027–2032
Table 28. Global Leukemia Molecular Diagnostics Revenue Market Share by Type (2027–2032)
Table 29. Global Leukemia Molecular Diagnostics Market Size by Application (US$ Million), 2021–2026
Table 30. Global Leukemia Molecular Diagnostics Revenue Market Share by Application (2021–2026)
Table 31. Global Leukemia Molecular Diagnostics Forecasted Market Size by Application (US$ Million), 2027–2032
Table 32. Global Leukemia Molecular Diagnostics Revenue Market Share by Application (2027–2032)
Table 33. North America Leukemia Molecular Diagnostics Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 34. North America Leukemia Molecular Diagnostics Market Size by Country (US$ Million), 2021–2026
Table 35. North America Leukemia Molecular Diagnostics Market Size by Country (US$ Million), 2027–2032
Table 36. Europe Leukemia Molecular Diagnostics Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 37. Europe Leukemia Molecular Diagnostics Market Size by Country (US$ Million), 2021–2026
Table 38. Europe Leukemia Molecular Diagnostics Market Size by Country (US$ Million), 2027–2032
Table 39. Asia-Pacific Leukemia Molecular Diagnostics Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 40. Asia-Pacific Leukemia Molecular Diagnostics Market Size by Region (US$ Million), 2021–2026
Table 41. Asia-Pacific Leukemia Molecular Diagnostics Market Size by Region (US$ Million), 2027–2032
Table 42. Latin America Leukemia Molecular Diagnostics Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 43. Latin America Leukemia Molecular Diagnostics Market Size by Country (US$ Million), 2021–2026
Table 44. Latin America Leukemia Molecular Diagnostics Market Size by Country (US$ Million), 2027–2032
Table 45. Middle East & Africa Leukemia Molecular Diagnostics Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 46. Middle East & Africa Leukemia Molecular Diagnostics Market Size by Country (US$ Million), 2021–2026
Table 47. Middle East & Africa Leukemia Molecular Diagnostics Market Size by Country (US$ Million), 2027–2032
Table 48. Ruiang Gene Company Details
Table 49. Ruiang Gene Business Overview
Table 50. Ruiang Gene Leukemia Molecular Diagnostics Product
Table 51. Ruiang Gene Revenue in Leukemia Molecular Diagnostics Business (US$ Million), 2021–2026
Table 52. Ruiang Gene Recent Development
Table 53. Zhishan Bio Company Details
Table 54. Zhishan Bio Business Overview
Table 55. Zhishan Bio Leukemia Molecular Diagnostics Product
Table 56. Zhishan Bio Revenue in Leukemia Molecular Diagnostics Business (US$ Million), 2021–2026
Table 57. Zhishan Bio Recent Development
Table 58. Zhijiang Bio Company Details
Table 59. Zhijiang Bio Business Overview
Table 60. Zhijiang Bio Leukemia Molecular Diagnostics Product
Table 61. Zhijiang Bio Revenue in Leukemia Molecular Diagnostics Business (US$ Million), 2021–2026
Table 62. Zhijiang Bio Recent Development
Table 63. Jinpujia Medical Company Details
Table 64. Jinpujia Medical Business Overview
Table 65. Jinpujia Medical Leukemia Molecular Diagnostics Product
Table 66. Jinpujia Medical Revenue in Leukemia Molecular Diagnostics Business (US$ Million), 2021–2026
Table 67. Jinpujia Medical Recent Development
Table 68. Merle Bio Company Details
Table 69. Merle Bio Business Overview
Table 70. Merle Bio Leukemia Molecular Diagnostics Product
Table 71. Merle Bio Revenue in Leukemia Molecular Diagnostics Business (US$ Million), 2021–2026
Table 72. Merle Bio Recent Development
Table 73. Herui Gene Company Details
Table 74. Herui Gene Business Overview
Table 75. Herui Gene Leukemia Molecular Diagnostics Product
Table 76. Herui Gene Revenue in Leukemia Molecular Diagnostics Business (US$ Million), 2021–2026
Table 77. Herui Gene Recent Development
Table 78. Aicon Bio Company Details
Table 79. Aicon Bio Business Overview
Table 80. Aicon Bio Leukemia Molecular Diagnostics Product
Table 81. Aicon Bio Revenue in Leukemia Molecular Diagnostics Business (US$ Million), 2021–2026
Table 82. Aicon Bio Recent Development
Table 83. Annuouda Company Details
Table 84. Annuouda Business Overview
Table 85. Annuouda Leukemia Molecular Diagnostics Product
Table 86. Annuouda Revenue in Leukemia Molecular Diagnostics Business (US$ Million), 2021–2026
Table 87. Annuouda Recent Development
Table 88. Beijing Wantai Company Details
Table 89. Beijing Wantai Business Overview
Table 90. Beijing Wantai Leukemia Molecular Diagnostics Product
Table 91. Beijing Wantai Revenue in Leukemia Molecular Diagnostics Business (US$ Million), 2021–2026
Table 92. Beijing Wantai Recent Development
Table 93. Haixi Bio Company Details
Table 94. Haixi Bio Business Overview
Table 95. Haixi Bio Leukemia Molecular Diagnostics Product
Table 96. Haixi Bio Revenue in Leukemia Molecular Diagnostics Business (US$ Million), 2021–2026
Table 97. Haixi Bio Recent Development
Table 98. Qiagen Company Details
Table 99. Qiagen Business Overview
Table 100. Qiagen Leukemia Molecular Diagnostics Product
Table 101. Qiagen Revenue in Leukemia Molecular Diagnostics Business (US$ Million), 2021–2026
Table 102. Qiagen Recent Development
Table 103. Abbott Company Details
Table 104. Abbott Business Overview
Table 105. Abbott Leukemia Molecular Diagnostics Product
Table 106. Abbott Revenue in Leukemia Molecular Diagnostics Business (US$ Million), 2021–2026
Table 107. Abbott Recent Development
Table 108. Kanglu Biotechnology Company Details
Table 109. Kanglu Biotechnology Business Overview
Table 110. Kanglu Biotechnology Leukemia Molecular Diagnostics Product
Table 111. Kanglu Biotechnology Revenue in Leukemia Molecular Diagnostics Business (US$ Million), 2021–2026
Table 112. Kanglu Biotechnology Recent Development
Table 113. Guangzhou Anbiping Company Details
Table 114. Guangzhou Anbiping Business Overview
Table 115. Guangzhou Anbiping Leukemia Molecular Diagnostics Product
Table 116. Guangzhou Anbiping Revenue in Leukemia Molecular Diagnostics Business (US$ Million), 2021–2026
Table 117. Guangzhou Anbiping Recent Development
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
Table 121. Authors List of This Report
List of Figures
Figure 1. Leukemia Molecular Diagnostics Picture
Figure 2. Global Leukemia Molecular Diagnostics Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global Leukemia Molecular Diagnostics Market Share by Type: 2025 vs 2032
Figure 4. PCR Features
Figure 5. FISH Features
Figure 6. DNA Sequencing Features
Figure 7. Gene Chip Features
Figure 8. Global Leukemia Molecular Diagnostics Market Size by Application (US$ Million), 2021–2032
Figure 9. Global Leukemia Molecular Diagnostics Market Share by Application: 2025 vs 2032
Figure 10. Clinical Diagnosis Case Studies
Figure 11. Drug Screening Case Studies
Figure 12. Research Case Studies
Figure 13. Leukemia Molecular Diagnostics Report Years Considered
Figure 14. Global Leukemia Molecular Diagnostics Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 15. Global Leukemia Molecular Diagnostics Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 16. Global Leukemia Molecular Diagnostics Market Share by Region: 2025 vs 2032
Figure 17. Global Leukemia Molecular Diagnostics Market Share by Players in 2025
Figure 18. Global Leukemia Molecular Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 19. The Top 10 and 5 Players Market Share by Leukemia Molecular Diagnostics Revenue in 2025
Figure 20. North America Leukemia Molecular Diagnostics Market Size YoY Growth (US$ Million), 2021–2032
Figure 21. North America Leukemia Molecular Diagnostics Market Share by Country (2021–2032)
Figure 22. United States Leukemia Molecular Diagnostics Market Size YoY Growth (US$ Million), 2021–2032
Figure 23. Canada Leukemia Molecular Diagnostics Market Size YoY Growth (US$ Million), 2021–2032
Figure 24. Europe Leukemia Molecular Diagnostics Market Size YoY Growth (US$ Million), 2021–2032
Figure 25. Europe Leukemia Molecular Diagnostics Market Share by Country (2021–2032)
Figure 26. Germany Leukemia Molecular Diagnostics Market Size YoY Growth (US$ Million), 2021–2032
Figure 27. France Leukemia Molecular Diagnostics Market Size YoY Growth (US$ Million), 2021–2032
Figure 28. U.K. Leukemia Molecular Diagnostics Market Size YoY Growth (US$ Million), 2021–2032
Figure 29. Italy Leukemia Molecular Diagnostics Market Size YoY Growth (US$ Million), 2021–2032
Figure 30. Russia Leukemia Molecular Diagnostics Market Size YoY Growth (US$ Million), 2021–2032
Figure 31. Ireland Leukemia Molecular Diagnostics Market Size YoY Growth (US$ Million), 2021–2032
Figure 32. Asia-Pacific Leukemia Molecular Diagnostics Market Size YoY Growth (US$ Million), 2021–2032
Figure 33. Asia-Pacific Leukemia Molecular Diagnostics Market Share by Region (2021–2032)
Figure 34. China Leukemia Molecular Diagnostics Market Size YoY Growth (US$ Million), 2021–2032
Figure 35. Japan Leukemia Molecular Diagnostics Market Size YoY Growth (US$ Million), 2021–2032
Figure 36. South Korea Leukemia Molecular Diagnostics Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. Southeast Asia Leukemia Molecular Diagnostics Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. India Leukemia Molecular Diagnostics Market Size YoY Growth (US$ Million), 2021–2032
Figure 39. Australia & New Zealand Leukemia Molecular Diagnostics Market Size YoY Growth (US$ Million), 2021–2032
Figure 40. Latin America Leukemia Molecular Diagnostics Market Size YoY Growth (US$ Million), 2021–2032
Figure 41. Latin America Leukemia Molecular Diagnostics Market Share by Country (2021–2032)
Figure 42. Mexico Leukemia Molecular Diagnostics Market Size YoY Growth (US$ Million), 2021–2032
Figure 43. Brazil Leukemia Molecular Diagnostics Market Size YoY Growth (US$ Million), 2021–2032
Figure 44. Middle East & Africa Leukemia Molecular Diagnostics Market Size YoY Growth (US$ Million), 2021–2032
Figure 45. Middle East & Africa Leukemia Molecular Diagnostics Market Share by Country (2021–2032)
Figure 46. Israel Leukemia Molecular Diagnostics Market Size YoY Growth (US$ Million), 2021–2032
Figure 47. Saudi Arabia Leukemia Molecular Diagnostics Market Size YoY Growth (US$ Million), 2021–2032
Figure 48. UAE Leukemia Molecular Diagnostics Market Size YoY Growth (US$ Million), 2021–2032
Figure 49. Ruiang Gene Revenue Growth Rate in Leukemia Molecular Diagnostics Business (2021–2026)
Figure 50. Zhishan Bio Revenue Growth Rate in Leukemia Molecular Diagnostics Business (2021–2026)
Figure 51. Zhijiang Bio Revenue Growth Rate in Leukemia Molecular Diagnostics Business (2021–2026)
Figure 52. Jinpujia Medical Revenue Growth Rate in Leukemia Molecular Diagnostics Business (2021–2026)
Figure 53. Merle Bio Revenue Growth Rate in Leukemia Molecular Diagnostics Business (2021–2026)
Figure 54. Herui Gene Revenue Growth Rate in Leukemia Molecular Diagnostics Business (2021–2026)
Figure 55. Aicon Bio Revenue Growth Rate in Leukemia Molecular Diagnostics Business (2021–2026)
Figure 56. Annuouda Revenue Growth Rate in Leukemia Molecular Diagnostics Business (2021–2026)
Figure 57. Beijing Wantai Revenue Growth Rate in Leukemia Molecular Diagnostics Business (2021–2026)
Figure 58. Haixi Bio Revenue Growth Rate in Leukemia Molecular Diagnostics Business (2021–2026)
Figure 59. Qiagen Revenue Growth Rate in Leukemia Molecular Diagnostics Business (2021–2026)
Figure 60. Abbott Revenue Growth Rate in Leukemia Molecular Diagnostics Business (2021–2026)
Figure 61. Kanglu Biotechnology Revenue Growth Rate in Leukemia Molecular Diagnostics Business (2021–2026)
Figure 62. Guangzhou Anbiping Revenue Growth Rate in Leukemia Molecular Diagnostics Business (2021–2026)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
